Literature DB >> 3345525

Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues.

M Tal1, M Wetzler, Z Josefberg, A Deutch, M Gutman, D Assaf, R Kris, Y Shiloh, D Givol, J Schlessinger.   

Abstract

The HER2/neu protooncogene was found to be amplified in 6 of 109 primary adenocarcinoma tumors. No HER2/neu amplification was found in 29 other primary nonadenocarcinomatous tumors. In two colon tumors, in addition to the amplification, DNA rearrangement of HER2/neu gene was also observed. The rearrangement was explored in detail in one tumor and it was shown to be confined to the 3' region of the gene. Moreover, this tumor expressed an aberrant HER2/neu polypeptide with a molecular weight of 190,000, which is larger by approximately 5,000 than the molecular weight of the normal HER2/neu protein. The aberrant HER2/neu protein was immunoprecipitated with site-specific antibodies against a synthetic peptide from the COOH-terminal end of the normal HER2/neu protein; it also displayed intrinsic protein tyrosine kinase activity leading to self-phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3345525

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Negative autoregulation of the neu gene is mediated by a novel enhancer.

Authors:  X Y Zhao; M C Hung
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  c-erbB-2 oncogene product expression and prognosis in gastric carcinoma.

Authors:  D A Hilton; K P West
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

3.  Karyotype peculiarities of human colorectal adenocarcinomas.

Authors:  L N Konstantinova; E W Fleischman; V I Knisch; A G Perevozchikov; B P Kopnin
Journal:  Hum Genet       Date:  1991-03       Impact factor: 4.132

4.  HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.

Authors:  Dong Il Park; Mun Su Kang; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Won Kon Han; Hungdai Kim; Seung Ho Ryu; Antonia R Sepulveda
Journal:  Int J Colorectal Dis       Date:  2006-09-01       Impact factor: 2.571

5.  Breast biopsy nuclear pellets are a convenient source of DNA for routine determination of Her-2/neu gene amplification.

Authors:  O Malka; Y Pollack; D Benharroch; Y Cohen; R Levy; I Yanai-Inbar; J Gopas
Journal:  Breast Cancer Res Treat       Date:  1991-09       Impact factor: 4.872

6.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Authors:  Anurag Singh; Patricia Greninger; Daniel Rhodes; Louise Koopman; Sheila Violette; Nabeel Bardeesy; Jeff Settleman
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

7.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

8.  Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma.

Authors:  Yao Zheng; Lin Wang; Jian-Ping Zhang; Jing-Yan Yang; Zhu-Mei Zhao; Xiao-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

Review 9.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.